相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Itziar Otano et al.
NATURE COMMUNICATIONS (2021)
A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
Cecile Geuijen et al.
NATURE COMMUNICATIONS (2021)
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
Matthew A. Lakins et al.
CLINICAL CANCER RESEARCH (2020)
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
Marlon J. Hinner et al.
CLINICAL CANCER RESEARCH (2019)
Twists and turns to translating 4-1BB cancer immunotherapy
Miguel F. Sanmamed et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
Xiaojie Yu et al.
CANCER CELL (2018)
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway
Todd Bartkowiak et al.
CLINICAL CANCER RESEARCH (2018)
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
S. Michael Chin et al.
NATURE COMMUNICATIONS (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer
Peter L. Stern et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4
Jay Harper et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Mark Yarchoan et al.
CLINICAL CANCER RESEARCH (2017)
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer
Donastas Sakellariou-Thompson et al.
CLINICAL CANCER RESEARCH (2017)
Therapeutic potential of anti-CD137 (4-1BB) monoclonal antibodies
Dass S. Vinay et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2016)
4-1BB agonism: adding the accelerator to cancer immunotherapy
Cariad Chester et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
4-1 BB agonists: multi-potent potentiators of tumor immunity
Todd Bartkowiak et al.
FRONTIERS IN ONCOLOGY (2015)
CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Yuwen Zhu et al.
CLINICAL CANCER RESEARCH (2014)
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye et al.
CLINICAL CANCER RESEARCH (2014)
Characterization and screening of IgG binding to the neonatal Fc receptor
Tobias Neuber et al.
MABS (2014)
Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Timothy S. Fisher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences
Weirong Wang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Roch Houot et al.
BLOOD (2009)
Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
Ke Wu et al.
CANCER RESEARCH (2009)
Costimulatory and coinhibitory receptors in anti-tumor immunity
Gregory Driessens et al.
IMMUNOLOGICAL REVIEWS (2009)
分享论文
